Select Page
  • You will be contacted by our booking team for your booster Covid-19 vaccine, 6 months after your second dose.
  • The main hub for BHWC patients is Brighton Racecourse although we are also using Portslade Health Centre and some of the other centres in Brighton & Hove.
  • The following patients are currently being offered a third dose COVID-19 booster vaccine:
    • those living in residential care homes for older adults
    • all adults aged 50 years or over
    • frontline health and social care workers
    • all those aged 16 to 49 years with underlying health conditions that put them at higher risk of severe COVID-19 (as set out in the green book), and adult carers
    • adult household contacts of immunosuppressed individuals
  • There are no contraindications between the flu jab and the third dose COVID-19 vaccine, which means if you are offered, you  can have the flu jab and the booster at the same time.
  • The Pfizer-BioNTech vaccine will be offered as the third booster dose irrespective of which product was used in the primary schedule. Where mRNA vaccines cannot be offered e.g. due to contraindication, vaccination with the AstraZeneca vaccine may be considered for those who received AstraZeneca vaccine in the primary course.
  • If you are housebound we will vaccinate you in your home, as we did previously. We will contact you to arrange this.
Q: I would really like to be given COVID booster asap – can you give me some advice please?
A: The 2nd dose gives immunity for 6 months so she will not need booster until 6 months after 2nd dose – You will be invited or you can book this nearer the time by calling 0300 303 8060.

For more information visit https://www.sussexhealthandcare.uk/keepsussexsafe/sussex-covid-19-vaccination-programme/

From the Green book Chapter 14a:

Studies of boosting in the UK have shown that a third dose of AstraZeneca, Moderna and Pfizer BioNTech vaccines successfully boosted individuals who had been primed with two doses of Pfizer BioNTech or AstraZeneca vaccine around 3 months earlier. Levels of IgG and pseudoneutralising antibody, including against Delta variant, were generally higher where an mRNA vaccine was used as either a heterologous or homologous boost, or where AstraZeneca was used as a heterologous boost after a primary course of PFizer BioNTech. Levels of antibody after an AstraZeneca boost in those primed with the same vaccine are as good or better than those seen after the second dose; these antibody
levels correlate with high levels of protection against severe disease and death. This finding was confirmed in a study where a third dose of AstraZeneca was given at a later time point (Flaxman et al, 2021).